On March 10, 2022 Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, reported that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16 at 8:00-8:30 AM EDT (Press release, Ocuphire Pharma, MAR 10, 2022, View Source [SID1234609916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 32nd Annual Healthcare Conference – March 15-17, 2022

Title: Ocuphire Pharma (OCUP) Company Presentation
Date: Wednesday, March 16, 2022
Time: 8:00 AM EDT
Presenter: Mina Sooch, CEO
Webcast Link: Register here
If you are interested in arranging a 1X1 meeting request or listening live or to a replay of the company presentation, please contact your bank conference representative or [email protected]. To access the archived recording for replay, please see the Investors and Events section of Ocuphire’s corporate website.

On March 10, 2022 Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported that it will present at the 34th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT (Press release, Delcath Systems, MAR 10, 2022, View Source [SID1234609915]). A webcast of the presentation will be available at: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].

On March 10, 2022 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in March 2022 (Press release, Mustang Bio, MAR 10, 2022, View Source(%E2%80%9CMustang%E2%80%9D)%20(NASDAQ,President%20and%20Chief%20Executive%20Officer%2C [SID1234609914]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Oppenheimer’s 32nd Annual Virtual Healthcare Conference: The company will participate in a fireside chat on Tuesday, March 15, 2022, at 4:00 p.m. ET and will participate in one-on-one meetings during the conference. A webcast of the company’s fireside chat will be available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting.
H.C. Wainwright’s Gene Therapy and Gene Editing Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Wednesday, March 30, 2022, at 7:00 a.m. ET and will remain available on the News & Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days after the meeting. The company will also participate in one-on-one meetings during the conference.
Cantor Fitzgerald’s Rare Orphan Disease Summit: The company will participate in a panel presentation on Wednesday, March 30, 2022, at 4:00 p.m. ET, titled, "Cell Therapy: How the Definition Has Expanded With Time, and the Potential Applications For Rare Diseases."

On March 10, 2022 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, reported that it will present new studies on its TGF- β program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana (Press release, Oncotelic, MAR 10, 2022, View Source [SID1234609913]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will demonstrate a close relationship between TGF-β expression and immune evasion by cancer and SARS-CoV-2. Details of the presentation are as follows:

Presentation Title: Mutational analysis of ORF-8 of SARS-CoV-2 – a window to immunotherapy. Session Title: Cancer Genomics. Session Category: Molecular and Cellular Biology/Genetics. Abstract Number: 2937

The AACR (Free AACR Whitepaper) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

In August 2021, the Company and GMP entered into a term sheet, including certain binding terms, to form a JV to develop Oncotelic’s drug portfolio and build out a manufacturing facility. Also, the Company had announced, and subsequently reported in our Quarterly Report on form 10-Q filed with the SEC on August 17, 2021, the intent to take the JV into an initial public offering ("IPO") at a future date. On February 14th, the Company and GMP agreed to extend the standstill terms of the term sheet until March 31, 2022 to permit the completion of the transaction.

"Oncotelic’s goal is to create novel immune based therapies for oncology and virology. Development of drugs is an expensive endeavor, and the JV is intended to ensure sufficient financial resources to get the Company’s portfolio to marketing approval and beyond." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

On March 10, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, reported that it will present at the Oppenheimer 32nd Annual Healthcare Conference being held virtually March 15-17 (Press release, Cue Biopharma, MAR 10, 2022, View Source [SID1234609912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will provide an updated corporate overview and discuss clinical progress from its ongoing clinical trials with CUE-101, its lead and representative drug product candidate from the IL-2 based CUE-100 series in development for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The Company will also discuss anticipated milestones and additional IL-2 based CUE-100 series pipeline progress, including its second IL-2 based candidate CUE-102 with an Investigational New Drug (IND) filing planned for the end of the first quarter 2022.

Presentation Details

Oppenheimer 32nd Annual Healthcare Conference
Date and Time: Thursday, March 17, 2022 at 11:20 a.m. EDT
Webcast link: View Source
A live and archived webcast of the presentation will be available in the Investor and Media section of the Company’s website at www.cuebiopharma.com. The webcast will be archived for 30 days.